Crossmark

Concept confirmation of the Treatment Administration Satisfaction Questionnaire (TASQ) in rare paroxysmal nocturnal hemoglobinuria

Published Online: 2021-06-21

Published Print: 2021-12

Authors

Doll, Helen https://orcid.org/0000-0002-1871-8710
Coşkun, Ufuk https://orcid.org/0000-0002-8184-4015
Hartford, Chris https://orcid.org/0000-0001-7095-0106
Tomazos, Ioannis https://orcid.org/0000-0003-0290-4583
Funding

Funding for this research was provided by:

Alexion Pharmaceuticals
License Information

Text and Data Mining valid from 2021-06-21

Version of Record valid from 2021-06-21
More Information

Article History

Received: 10 September 2020

Accepted: 12 May 2021

First Online: 21 June 2021

Declarations

:

: Before recruiting subjects, all study documents were submitted and approved by the National Health Service Central Research Ethics Committee, approval number: 17/WS/0260. This study was conducted in compliance with Good Clinical Practice guidelines, including International Conference on Harmonization Guidelines and consistent with the most recent version of the Declaration of Helsinki. In addition, all applicable local laws and regulatory requirements were adhered to throughout the study.

: Not applicable – all data in publication is anonymized.

: HD, UC, and CH declare that they have no competing interests to disclose. IT is an employee of and a stockholder in Alexion Pharmaceuticals, Inc.

Document is current